Perinatal Hypoxia-Inducible Factor Stabilization Preserves Lung Alveolar and Vascular Growth in Experimental Bronchopulmonary Dysplasia
- 15 October 2020
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (8), 1146-1158
- https://doi.org/10.1164/rccm.202003-0601OC
Abstract
Rationale: Antenatal inflammation with placental dysfunction is strongly associated with high bronchopulmonary dysplasia (BPD) risk in preterm infants. Whether antenatal or postnatal HIF (hypoxia-inducible factor) augmentation can preserve lung structure and function and prevent pulmonary hypertension after intrauterine inflammation is controversial. Objectives: To determine whether antenatal or postnatal prolylhydroxylase inhibitor (PHi) therapy increases lung HIF expression, preserves lung growth and function, and prevents pulmonary hypertension in a rat model of chorioamnionitis-induced BPD caused by antenatal inflammation. Methods: Endotoxin (ETX) was administered to pregnant rats by intraamniotic injection at Embryonic Day 20, and pups were delivered by cesarean section at Embryonic Day 22. Selective PHi drugs, dimethyloxalylglycine or GSK360A, were administered into the amniotic space at Embryonic Day 20 or after birth by intraperitoneal injection for 2 weeks. Placentas and lung tissue were collected at birth for morphometric and Western blot measurements of HIF-1a, HIF-2a, VEGF (vascular endothelial growth factor), and eNOS (endothelial nitric oxide synthase) protein contents. At Day 14, lung function was assessed, and tissues were harvested to determine alveolarization by radial alveolar counts, pulmonary vessel density, and right ventricle hypertrophy (RVH). Measurements and Main Results: Antenatal PHi therapy preserves lung alveolar and vascular growth and lung function and prevents RVH after intrauterine ETX exposure. Antenatal administration of PHi markedly upregulates lung HIF-1a, HIF-2a, VEGF, and eNOS expression after ETX exposure. Conclusions: HIF augmentation improves lung structure and function, prevents RVH, and improves placental structure following antenatal ETX exposure. We speculate that antenatal or postnatal PHi therapy may provide novel strategies to prevent BPD due to antenatal inflammation.This publication has 86 references indexed in Scilit:
- The Ubiquitin-Proteasome System Meets AngiogenesisMolecular Cancer Therapeutics, 2012
- Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasiaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro in fetal sheepAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- HIF and the LungAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Moderate postnatal hyperoxia accelerates lung growth and attenuates pulmonary hypertension in infant rats after exposure to intra-amniotic endotoxinAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research NetworkPEDIATRICS, 2010
- Fetal Growth Restriction and Chronic Lung Disease Among Infants Born Before the 28th Week of GestationPEDIATRICS, 2009
- HIF1α Is Essential for Normal Intrauterine Differentiation of Alveolar Epithelium and Surfactant Production in the Newborn Lung of MiceOnline Journal of Public Health Informatics, 2008
- Chronic intrauterine pulmonary hypertension increases endothelial cell Rho kinase activity and impairs angiogenesis in vitroAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Bronchopulmonary DysplasiaAmerican Journal of Respiratory and Critical Care Medicine, 2007